Moshirfar Majid, Kuang Grace T., Ronquillo Yasmyne
University of Utah/John Moran Eye Center; Hoopes Vision/HDR Research Center; Utah Lions Eye Bank
UT McGovern Medical School
Alkaptonuria is a rare autosomal recessive disorder that arises from a mutation of the homogentisate 1,2-dioxygenase () gene, resulting in a deficiency of the enzyme HGD. This enzyme plays a role in the phenylalanine and tyrosine degradation pathways by catabolizing the tyrosine intermediate metabolite homogentisic acid (HGA) into maleylacetoacetic acid (Figure 1). Deficiency of the HGD enzyme results in the abnormal accumulation of upstream precursors HGA, tyrosine, and phenylalanine. In particular, the buildup and deposition of HGA is the major contributor to the classic manifestations and consequences of the disease, including homogentisic aciduria, ochronosis, and ochronotic osteoarthropathy. Alkaptonuria leads to dysfunctions in various tissues throughout the body; this article will broadly cover the prominent presentations and focus on ocular manifestations of the disorder in particular. Early identification and diagnosis of the disorder are imperative for management and treatment as complications can be sight-threatening, including astigmatism, central vein occlusion, glaucoma, and blindness. The first case of alkaptonuria is believed to have presented in 1500 BC as found in the Egyptian mummy . Biopsy of the body’s hip cartilage and intervertebral discs in 1979 demonstrated extensive calcification and HGA pigmentation consistent with the process of ochronosis. Cases of the disease reported in the 16 century centered around the observation of dark urine, which continued to be the identifying feature and namesake of the “black urine disease” through the 19 century. In 1859, Dr. Carl Boedeker found that adding alkali to these patients’ urine produced the appearance of dark discoloration (later discovered to be due to HGA’s reducing power). He subsequently named the disease “alkaptonuria” in reference to “alkali” in Arabic, meaning “alkali,” “alkali” in Greek, meaning “to suck up oxygen greedily in alkali,” and “alkapton” in German, meaning “a reducing compound.” Alkaptonuria is a disease that occupies a noteworthy place in the histories of biochemistry, genetics, and medicine. In 1902, it was the first medical disorder reported to adhere to the Mendelian principles of autosomal recessive inheritance by Sir Archibald Garrod. Garrod deduced that all cases of alkaptonuria reported at the time required certain genetic contributions from both parents. In other words, the spectrum of outward manifestations could all be traced back to a specific underlying genetic trait, emphasizing the impact of science and genetics on the human constitution. At the time, many debilitating diseases were already noted to be more prevalent in consanguineous marriages, but few reports addressed consanguinity from a strictly scientific perspective. By connecting alkaptonuria to a genetic basis and referring to the similar gametes passed on by consanguineous parents, Garrod provided scientific evidence for some deleterious effects of consanguineous unions. In his 1908 Croonian Lecture to the Royal College of Physicians, Garrod also later used alkaptonuria as an example to demonstrate his concept of “the inborn error of metabolism,” now a widely used term applied to genetic disorders of innate metabolic pathways such as alkaptonuria.
黑尿症是一种罕见的常染色体隐性疾病,由尿黑酸1,2 -双加氧酶(HGD)基因突变引起,导致HGD酶缺乏。该酶通过将酪氨酸中间代谢产物尿黑酸(HGA)分解代谢为马来酰乙酰乙酸,在苯丙氨酸和酪氨酸降解途径中发挥作用(图1)。HGD酶缺乏导致上游前体物质HGA、酪氨酸和苯丙氨酸异常蓄积。特别是,HGA的蓄积和沉积是该疾病典型表现和后果的主要原因,包括尿黑酸尿症、褐黄病和褐黄病性骨关节病。黑尿症会导致全身各个组织功能障碍;本文将广泛涵盖其主要表现,并特别关注该疾病的眼部表现。由于并发症可能威胁视力,包括散光、中央静脉阻塞、青光眼和失明,因此早期识别和诊断该疾病对于管理和治疗至关重要。据信,第一例黑尿症病例出现在公元前1500年的埃及木乃伊身上。1979年对人体髋部软骨和椎间盘的活检显示,存在广泛的钙化和HGA色素沉着,与褐黄病的过程一致。16世纪报告的该疾病病例主要围绕对深色尿液的观察,在整个19世纪,深色尿液一直是“黑尿病”的识别特征和名称来源。1859年,卡尔·伯德克博士发现,向这些患者的尿液中添加碱会使其变黑(后来发现这是由于HGA的还原能力)。他随后根据阿拉伯语中的“alkali”(意为“碱”)、希腊语中的“alkali”(意为“在碱中贪婪地吸收氧气”)以及德语中的“alkapton”(意为“一种还原化合物”),将该疾病命名为“alkaptonuria”。黑尿症在生物化学、遗传学和医学史上占有重要地位。1902年,阿奇博尔德·加罗德爵士首次报告了一种遵循常染色体隐性遗传孟德尔原理的医学疾病,即黑尿症。加罗德推断,当时报告的所有黑尿症病例都需要父母双方特定的基因贡献。换句话说,所有外在表现都可以追溯到一个特定的潜在遗传特征,这强调了科学和遗传学对人类体质的影响。当时,人们已经注意到许多使人衰弱的疾病在近亲婚姻中更为普遍,但很少有报告从严格的科学角度探讨近亲关系。通过将黑尿症与遗传基础联系起来,并提及近亲父母传递的相似配子,加罗德为近亲结合的一些有害影响提供了科学证据。在1908年他给皇家内科医师学院的克罗onian讲座中,加罗德后来还以黑尿症为例,阐述了他的“先天性代谢缺陷”概念,如今这一术语广泛应用于先天性代谢途径的遗传疾病,如黑尿症。